Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-23

Clinical Trial Update: Pomalidomide for the Treatment of Bleeding in HHT [Phase 2]

View source ↗

Summary

Phase 2 trial of pomalidomide for reducing bleeding in hereditary hemorrhagic telangiectasia has completed and results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pomalyst (pomalidomide)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Telangiectasia, Hereditary Hemorrhagic | Phase 2 | Status: COMPLETED | Results posted: 2024-10-23